Skip to content
Screener

Acadia Pharmaceuticals ACAD Total Cost of Revenue

Total Cost of Revenue at other companies

Biogen logo
BiogenBIIB
$776.9M+28.4%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$13.8M+50.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$1.53M-87.7%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$461.69M+5.3%

Segments

By segment

See full
Reportable Segment Aggregation Before Other Operating$12.79M+52.5%

Other financials

Income statement

See full
Revenue$308.0M+16.4%
Gross profit$279.6M+14.7%
Operating income$37.8M+16.9%
Net income$31.5M+18.1%
EPS (diluted)$0.18+12.5%

Balance sheet

See full
Cash & equivalents$385.0M+51.8%
Total debt$73.9M+31.2%
Total equity$1.3B+58.9%
Total assets$1.7B+42.2%

Cash flow

See full
Operating cash flow$100.8M+57.6%
CapEx$5.1M+1,613%
Free cash flow$95.7M+50.3%

Valuation

See full
Market cap$4.9B+23.1%
Enterprise value$4.59B+21.3%
P/E12.9×-5.0×
P/S4.3×+0.4×

Profitability

See full
Gross margin91.1%-0.8pp
Operating margin7.6%-15.7pp
Net margin33.4%+11.6pp
FCF margin18.9%—

Returns & leverage

See full
Return on equity35.7%+2.6pp
Debt / equity0.1×0.0×
Current ratio3.4×+0.5×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333243
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Product sales, net$307,959$264,566$576,021$508,882
Total revenues307,959264,566576,021508,882
Operating expenses
Cost of product sales28,31620,73453,10741,126
Research and development81,55577,951158,423156,216
Selling, general and administrative160,252133,507331,271259,877
Total operating expenses270,123232,192542,801457,219
Income from operations37,83632,37433,22051,663

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Acadia Pharmaceuticals's total cost of revenue?
Acadia Pharmaceuticals (ACAD) reported total cost of revenue of $28.32M in Q2 2026.
How has Acadia Pharmaceuticals's total cost of revenue changed year-over-year?
Acadia Pharmaceuticals's total cost of revenue increased by 36.6% year-over-year, from $20.73M to $28.32M.
What is the long-term trend for Acadia Pharmaceuticals's total cost of revenue?
Over 4 years (2021 to 2025), Acadia Pharmaceuticals's total cost of revenue has grown at a 46.8% compound annual growth rate (CAGR), from $19.14M to $89M.
What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.

Ask your AI about Acadia Pharmaceuticals's total cost of revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude